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treatment of non-infectious uveitis: a
systematic review protocol
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Abstract
Background: Non-infectious uveitis represents a sub-type of intraocular inflammation often associated with
disorders of immune dysregulation. If untreated, the intraocular inflammation may progress to severe visual
impairment and blindness. Current treatment is heavily reliant on systemic corticosteroid, often at doses associated
with severe side effects. There is a need for efficacious corticosteroid-sparing immunomodulatory therapy for these
patients. Current immunomodulators include various immunosuppressants and biologics but mammalian target of
rapamycin (mTOR) inhibitors (such as sirolimus and everolimus) may also be contenders for this role.
The systematic review proposed here will evaluate the evidence for the use of sirolimus and everolimus in the
context of non-infectious uveitis.
Method/design: Standard systematic review methodology will be used to identify, select and extract data from
any comparative or non-comparative study of mTOR inhibitors in patients with non-infectious uveitis excluding
case reports. Searches of bibliographic databases (MEDLINE, EMBASE, The Cochrane Library and CINAHL) and clinical
trials registers will be performed, with no restriction on language or date of publication. Translation of non-English
language articles will be undertaken where necessary.
The primary outcome of interest will be uveitis activity as measured by vitreous haze. Secondary outcomes will
include other pre-specified measures of uveitis activity (such as anterior chamber cells or central macular thickness)
best corrected visual acuity, heath-related quality of life, requirement for concurrent treatment and adverse events.
Risk of bias assessment will be performed appropriate to each study design. Study selection, data extraction and
risk of bias assessment will be undertaken by two reviewers independently. Data will be grouped, tabulated and
narratively synthesised. Meta-analysis will be undertaken where appropriate clinical and methodological
homogeneity exists. The review will be published according to PRISMA guidance.
Discussion: Studies of various designs have investigated the clinical use of mTOR inhibitors for non-infectious
uveitis, and a large international randomised controlled trail of sirolimus for non-infectious uveitis is due to report.
The findings of this systematic review will help inform ophthalmologists and aid the improvement of treatment
protocols for non-infectious uveitis with regard to the use of mTOR inhibitors.
Systematic review registration: PROSPERO CRD42017056390
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Background
Uveitis is a serious and potentially blinding condition
and is a significant cause of legally recognised blindness
in the working-age population in many parts of the
world [1–3]. Most cases of non-infectious uveitis appear
to be autoimmune in nature, occurring in either isola-
tion (termed ‘idiopathic uveitis’) or in association with
systemic conditions featuring immune dysregulation
(e.g. sarcoidosis, Behcet’s disease) [2, 4, 5].
First-line treatment usually involves immunosuppres-
sion with corticosteroids, which can be delivered by top-
ical, local (intraocular injections or implants) or systemic
(often oral prednisolone) routes [6]. Corticosteroids
achieve rapid and effective control of uveitis, but are
limited by development of severe side effects, which be-
come particularly prevalent with increasing doses and
prolonged use [7]. Safe maintenance doses of corticoste-
roids are generally considered to be less than 10 mg of
prednisolone orally per day [8].
Patients requiring high doses of corticosteroids, and those
in whom disease is not adequately controlled by corticoste-
roids, require the addition of second-line treatments [8].
Treatment options include mycophenolate mofetil, azathio-
prine and calcineurin inhibitors (such as tacrolimus and
ciclosporin); however, these agents lack the speed of onset
and efficacy of corticosteroids and many are associated with
the development of different, but equally limiting side ef-
fects [5]. Multiple second-line agents may be used in com-
bination, and it is common to switch between classes to
achieve the desired therapeutic effect. Biologic therapies
and cytotoxic alkylating agents may also be used in severe
or recalcitrant disease [5, 8]. There remains a clear need for
efficacious steroid-sparing immunomodulatory therapy for
patients with non-infectious uveitis, aiming to achieve uve-
itis control at a cost of the fewest possible side effects [5].
Mammalian target of rapamycin (mTOR) inhibitors
have recently emerged as an area of interest in ophthal-
mology and may be contenders for this role. mTOR in-
hibitors are a class of immunomodulatory agents which
mediate their anti-inflammatory effects through inhib-
ition of T cell function. The class includes sirolimus (also
known as rapamycin) and everolimus [5, 8]. These
agents inhibit the action of mTOR, which is a serine/
threonine kinase with effects on many cell processes [9].
In the context of T cells, the mTOR inhibitors interfere
with signal transduction downstream of the cytokine re-
ceptor for IL-2, preventing IL-2 from causing T cell pro-
liferation and differentiation [10, 11]. This may have a
beneficial effect in the context of uveitis, as the immune
dysfunction in non-infectious uveitis is thought to be
primarily T cell mediated [2, 11].
A number of studies have investigated mTOR inhibi-
tors in non-infectious uveitis. A scoping search of the
Cochrane Library and the international prospective
register of systematic reviews (PROSPERO) has revealed
no published or ongoing systematic reviews. It is there-
fore timely to perform a systematic review to evaluate
the evidence for the use of sirolimus and everolimus in
the context of non-infectious uveitis.
Methods/design
Aim
The aim of the review is to assess the effectiveness and
safety of the mTOR inhibitors sirolimus and everolimus for
the treatment of non-infectious uveitis. This will be achieved
by conducting a systematic review of studies which:
 Evaluate or describe the use of an mTOR inhibitor
(sirolimus or everolimus) in the context of human
non-infectious uveitis
 Compare an mTOR inhibitor to a non-
pharmacological or pharmacological treatment
Standard protocol-guided systematic review methods
will be used.
This systematic review protocol has been registered in
the international prospective register of systematic reviews
(PROSPERO) database (ref. CRD42017056390) and re-
ported according to Preferred Reporting Items for System-
atic Reviews and Meta-Analyses Protocols (PRISMA-P)
guidelines (see Additional file 1).
Searches
The following sources will be searched for literature to
review:
 Bibliographic databases of published studies
○ MEDLINE (Ovid)
○ MEDLINE in process
○ EMBASE (Ovid)
○ CINAHL (EBSCO)
○ The Cochrane Library (CENTRAL Register of
Controlled Trials)
 Registers of clinical trials
○WHO International Clinical Trials Registry
Platform (ICTRP) portal (www.who.int/ictrp)
which comprises a portal to multiple registers
including Clinicaltrials.gov, the European Clinical
Trials Database (EudraCT;
www.clinicaltrialsregister.eu) and the International
Standard Randomised Controlled Trials Number
database (ISRCTN; www.controlled-trials.com)
 Abstract and Conference Proceedings
○ British Library ZETOC
○ Conference Proceedings Citation Index (Web
of Science)
 Grey Literature
○ OpenGrey (www.opengrey.eu)
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For bibliographic databases, the search strategy will
combine index and free text terms for the mTOR in-
hibitors both as a class and as individual drugs (such
as sirolimus and everolimus), and the condition
(non-infectious uveitis). A sample search strategy for
MEDLINE is provided in Appendix 1, which will be
adapted for use in each database.
The other sources listed above will be searched in a
more iterative way, where a complex search strategy
cannot be used. There will be no restriction on the lan-
guage or year of publication. Search results will be en-
tered into an EndNote (Thomson Reuters) database and
duplicate entries removed.
Selection criteria
The following criteria will be used to select literature for
review:
 Study design
○ Any study design will be included excluding
single case reports.
 Participants
○ Participants of any age, gender or ethnicity
with non-infectious uveitis
 Intervention and comparator
○ Intervention: an mTOR inhibitor
○ Comparator (where present): Any comparator,
for example this may be an mTOR inhibitor,
another pharmacological agent, or the use of
no agent or placebo.
 Outcomes
○ Outcomes will not be used to select studies.
Outcomes important for the aims of this
review are:
○ Primary outcome: clinical assessment of uveitis
activity by vitreous haze score [4]
○ Secondary outcomes:
▪ Other single clinical assessments of uveitis activity
• Anterior chamber cells (by SUN grade [4])
• Presence of active inflammatory
retinovascular lesion(s)
• Presence of active inflammatory chorioretinal
lesion(s)
• Central macular thickness
▪ Composite measure of uveitis activity
• Time to treatment failure
▪ Best corrected visual acuity (BCVA)
▪ Heath-related quality of life
▪ Concurrent requirement of corticosteroids to
control uveitis
▪ Concurrent requirement of other
immunomodulatory treatment to control
uveitis
▪ Adverse events
Vitreous haze was chosen as the primary outcome, as
firstly it has been identified by the FDA and other regu-
latory authorities as being a preferred trial endpoint for
disease activity in uveitis of the posterior segment of the
eye, and secondly, it is one of the commonest endpoints
used in such trials [12]. Furthermore, a scoping search
of mTOR inhibitor studies identified this as a common
endpoint in these trials. We recognise however that vit-
reous haze is of limited intuitive value to patients, for
whom an improvement in best corrected visual acuity or
health-related quality of life may be more meaningful.
These will be analysed as secondary outcomes in our
systematic review, but it is widely acknowledged that
neither are sufficiently sensitive over normal trial time-
scales to be used as the endpoint in clinical trials of uve-
itis, due to the indirect nature of disease activity to
visual outcome [13].
Selection process
The study selection process will be conducted in two
stages:
 Title and abstract of the articles identified by the
search strategy will be screened in order to remove
irrelevant records.
 The full text of potentially relevant articles will be
retrieved and assessed against the selection criteria
above
Two reviewers will independently assess articles at
both stages. Any disagreements will be resolved by dis-
cussion and if required referral to a third reviewer. Both
stages of the selection process will be piloted and if ne-
cessary modified. The selection process will be illus-
trated using a PRISMA flow diagram, and details of
articles excluded in the second (full text) stage will be
recorded, along with the reason for exclusion [14].
Articles of non-English language will be translated (in
part or wholly) to aid study selection and analysis.
Data extraction
Two reviewers will independently extract data from the
included articles. Any differences will be resolved by dis-
cussion, and if required referral to a third reviewer. A
standardised, piloted data extraction form will be used.
Study authors and publishing bodies may be contacted if
further information is required.
For each study, the following information (but not lim-
ited to) will be extracted:
 Study characteristics
○ Authors, publication year, title, journal, study
design, setting, sample size, length of follow up,
and analysis.
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 Participant characteristics
○ Patient selection and recruitment criteria,
patient characteristics (demographic data,
number, age, gender, ethnicity, socioeconomic
status), diagnosis of non-infectious uveitis
(including but not limited to: idiopathic,
sarcoidosis, birdshot chorioretinopathy,
Behcet’s disease), comorbidities, co-medication,
information regarding prior uveitis treatment.
 Intervention and comparator
○ Pharmacological agents studied, regimen (dose,
frequency of administration, route of
administration), comparator details (where
present), differences in underlying care
between treatment groups.
 Outcomes and findings
○ Outcomes being measured and results for each
outcome, precision and statistical test results
for each outcome, completeness of follow-up
for each outcome.
Quality assessment
Two reviewers will independently assess the quality of
the included articles. Any differences will be resolved by
discussion, and if required referral to a third reviewer.
The Cochrane Handbook Risk of Bias tool will be used
for RCTs [15].
Non-randomised controlled trials will also be assessed
using the risk of bias tool for RCTs, accepting that cri-
teria for randomisation and allocation concealment are
not relevant.
The guidelines in Chapter 13 of the Cochrane Hand-
book will be followed for prospective controlled observa-
tional studies [15], however a minimum assessment can
be made using the risk of bias tool for RCTs, again
accepting than not all criteria may be relevant. The most
relevant criteria to assess in these studies would relate to
how groups were selected, differences in participant
characteristics, losses to follow-up, biases and confound-
ing in outcome assessment. The new Risk Of Bias In
Non-randomized Studies - of Interventions (ROBINS-I)
tool will also be used as a pilot [16].
The Newcastle-Ottawa Scale will be used to assess any
case-controlled studies [17].
Case series will be assessed according to the guid-
ance of the Centre for Reviews and Dissemination
(York) [18].
Analysis
Studies will be grouped by the intervention, comparator
(if any) and design. Data will be tabulated and a narra-
tive synthesis of evidence will be conducted for each
outcome of relevance to the review and supported with
a meta-analysis where appropriate.
Results for study outcomes may be presented using a var-
iety of different measures, in continuous, discrete or dichot-
omous forms, within the same study or between studies.
For example, visual acuity may be reported in me-
ters or feet from Snellen charts, LogMAR scores, or
letters or lines read from ETDRS charts. Changes in
acuity may be presented as any of these, or as a pro-
portion passing over a threshold. Data conversion be-
tween formats for further analysis will be considered;
however, any conversion will be done with due cau-
tion and regard to known issues, and the use of data
conversion will be explicitly stated [19].
Regarding vitreous haze, which is commonly scored in
clinical practice and research with the SUN/Nussenblatt
scoring system, we are aware of a modification to this tool
in occasional use, comprising an additional step to the
established five-step scale. The additional step does not
affect the value of the other Nussenblatt grading scores.
This will preclude the combination of such studies with
others where proportion of participants with a fixed step
change (e.g. a proportion of participants with a two-step
change) is the outcome metric, but not where the propor-
tion having a fixed score is the metric (e.g. no haze) as the
latter is the same on the original and modified scales.
Should multiple time-point data be available, either within
the same study or between studies, data will be categorised
for analysis by the post-intervention follow-up period. This
will use groups of ≤ 3 months, > 3 and ≤ 6 months and >
6 months. Where appropriate, the > 6-month category may
be further split up if long-term data is available.
For each time period for each outcome, studies contrib-
uting data will be assessed for, and where possible grouped
according to, clinical and methodological homogeneity.
This will determine the feasibility for undertaking
meta-analysis and if undertaken whether a random effects
or fixed effect model is most appropriate [20]. Data from
differing study designs will not be pooled.
The I2 statistic (the percentage of data variability due
to study heterogeneity) will be reported for each ana-
lysis undertaken. If a meta-analysis comprising 10 or
more studies is undertaken, the possibility of publica-
tion bias will be investigated and a funnel plot con-
structed [21].
Where multiple studies report comparable continuous
data, data using the same scale may be pooled using re-
ported mean differences. Data on different scales may be
pooled to derive a standardised mean difference. Sub-
group analysis will be considered if appropriate.
If head-to-head studies comparing different mTOR
agents exist, direct comparison of interventions will be
undertaken. If multiple randomised controlled trials
encompassing different mTOR agents and with differing
comparators are found, the potential for undertaking in-
direct treatment comparisons will be considered to
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estimate a relative effect of the agents. Such comparison
will be dependent on the studies available, and key as-
sumptions regarding homogeneity, similarity and
consistency of the studies [22, 23].
As the intervention under review comprises two agents
(sirolimus and everolimus), evidence of the efficacy of the
overall mTOR inhibitor class will be discussed to report
on the consistency and magnitude of the overall class ef-
fect. Where available, comparison between the mTOR in-
hibitor class and other classes of agent will also be
considered.
It is acknowledged that the number of studies in-
cluded in this review is likely to be small and thus
many of the analyses outlined above will not at the
moment be possible. However, these methods are re-
ported as this protocol is intended to inform future
updates to this review where newer evidence may
allow for these analyses.
Reporting
This review and its findings will be reported in accord-
ance with PRISMA guidelines [14]. The strengths and
weaknesses of review methodology and evidence avail-
able will be discussed in relation to the external and in-
ternal validity of the findings. The review findings will
be discussed in the context of current and future clinical
practice regarding non-infectious uveitis, and possible
future research in this area.
Discussion and potential impact
Non-infectious uveitis is a potentially blinding inflam-
matory condition which often requires the prolonged
use of high doses of corticosteroids. This can result
in a significant burden of systemic steroid side effects,
and there is an increasing clinical need for effective
second-line therapeutics in order to achieve uveitis
control, whilst reducing the need for excessive steroid
doses (so-called steroid-sparing therapies). Various
immunomodulatory therapies can be used as
second-line agents for uveitis; however, these agents
are often limited by a slower onset of action and re-
duced efficacy compared to corticosteroids (reducing
their steroid-sparing potential), whilst being associated
with different but equally detrimental side effects.
There is a need to consider the evidence for alternative
second-line therapeutic agents with more favourable
characteristics, and the mTOR inhibitors appear to be
contenders for this role.
Second-line therapeutic agents are often introduced
into ophthalmology after showing efficacy for inflam-
matory disease in other medical specialties, notably
transplant immunosuppression and rheumatology
[24]. Such agents are frequently used for years in an
‘off-label’ capacity in ophthalmology, based on clinical
anecdote or personal experience, and few agents have
high-level evidence to support their efficacy in uveitis
[24]. This has led to considerable variability in the
decision making process for second-line agents in
uveitis.
Challenges in the attainment of high-level evidence
for uveitis include the low incidence and prevalence
of uveitis in the general population [5], and a hetero-
geneous aetiological basis with a historically inconsist-
ent classification of uveitis phenotypes [24].
These challenges are gradually being addressed: the
Standardisation of Uveitis Nomenclature group has
worked to establish unified descriptions for uveitis
which will aid in clinical practice, as well as collabor-
ation and analysis across treatment centres [4]. Fur-
thermore, larger, randomised and even multi-centre
trials are becoming more common to evaluate new
agents.
The mTOR inhibitors represent a small class of
agents that, until recently, have been relatively
neglected in ophthalmology. Like many second-line
uveitis agents, they have a background in transplant im-
munosuppression; however, modern ophthalmic inter-
est can be demonstrated by the imminent reporting of
an international multicentre randomised controlled
trial of sirolimus for non-infectious uveitis.
Therefore, it is timely to undertake a systematic re-
view to examine the evidence for the use of mTOR
inhibitors in non-infectious uveitis. Consequently, this
review will clarify the available evidence for ophthal-
mologists and clinical decision makers regarding the
potential role of mTOR inhibition in uveitis treatment
protocols, in terms of agent efficacy, adverse event
rates and the capability for corticosteroid dose
reduction.
Appendix 1
Table 1 MEDLINE sample search strategy
Search number Search details
1 Exp Uveitis/
2 (Uveitis OR Uveitic) ti, ab.
3 1 or 2
4 (Sirolimus OR rapamycin OR Rapamune
OR 53123–88-9) ti. ab.
5 (Everolimus OR Afinitor OR Certican OR RAD 001
OR RAD001 OR SDZ RAD) ti. ab.
6 (Deforilimus OR Ridoforilimus OR AP23573
OR MK-8669) ti. ab.
7 (Temsirolimus OR CCI-779) ti. ab.
8 Exp mTOR inhibitor/
9 4 or 5 or 6 or 7 or 8
10 3 and 9
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